Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.
The diabetes treatment landscape is rapidly evolving, with new combination therapies and oral GLP-1 medications, positioning pharmacists to have an important role in personalizing care.
Based on the updated label, new pharmacodynamic data have been added for a better understanding of the drug for individuals with attention-deficit/hyperactivity disorder (ADHD).
Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.
The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.
